VANDA Pharmaceuticals has compiled a report titled the “Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia" for Schizophrenia Research, the official journal of the Schizophrenia International Research Society.
13/03/2009
NOVABAY Pharmaceuticals has announced preclinical animal data showing that NVC-422, the company's lead Aganocide compound, was effective in treating subcutaneous dermatophyte (skin fungus) infections.
16/03/2009
The CSIRO has patented a microscopy method designed to measure the shape and size of proteins, helping medicinal research target them through pharmaceuticals.
05/02/2009
NEUREN Pharmaceuticals says it has obtained US$14m ($17.58m) of additional funding from the US Army, funding most of the costs for the upcoming NNZ-2566 Phase 2 trial.
03/07/2009
SPECTRUM Pharmaceuticals has announced the FDA has granted Fast Track Designation for the investigation of apaziquone (EOquin) for the treatment of non-muscle invasive bladder cancer.
24/07/2009
SIGMA-ALDRICH and Sangamo BioSciences have announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.
06/10/2009
PROGEN Pharmaceuticals Limited has announced new preclinical data on PG545, a dual antiangiogenic and anti-heparanase inhibitor, will be presented at an international cancer therapeutics conference.
15/10/2009
BAYER has announced its tablet treatment of unresectable hepatocellular carcinoma (HCC), Nexavar (sorafenib), has received approval in Japan by the Ministry of Health, Labour and Welfare (MHLW).
26/05/2009
TGEN CLINICAL Research Services at Scottsdale Healthcare has announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands
29/09/2009
The University of Queensland (UQ) received $1.66 million in funding from the Federal government's Linkage Infrastructure, Equipment and Facilities (LIEF) scheme.
03/12/2009
A NEW DRUG designed to “seek and destroy” common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
06/10/2009
The University of Sydney has announced its receipt of funding from the Federal government's Linkage Infrastructure, Equipment and Facilities (LIEF) scheme.
03/12/2009